Phase 1 and 2 trials with CD19-CAR-engineered NK cells have shown impressive responses in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) or chronic lymphocytic leukemia (CLL). Here, CD19 is linked to non-Hodgkin lymphoma.